Vaxart, Inc. (VXRT): R&D Expense
$201.58M
Year ended 2025-12-31
$184.26M
Trailing 12 months to 2026-06-30
+35.5%
3-year compound annual growth
+59.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $201.58M | +171.6% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $74.21M | +8.9% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $68.14M | -15.9% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $81.05M | +66.3% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $48.75M | +145.4% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $19.86M | +36.6% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $14.54M | -15.8% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $17.27M | +39.8% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $12.36M | n/a | 2019-02-06, From 2017-01-01 |
| No annual figure between 2016-06-30 and 2017-12-31. | |||
| 2016-06-30 | $26.30M | +32.8% | 2017-09-01, From 2015-07-01 |
| 2015-06-30 | $19.80M | +13.1% | 2016-09-13, From 2014-07-01 |
| 2014-06-30 | $17.50M | -12.1% | 2016-09-13, From 2013-07-01 |
| 2013-06-30 | $19.90M | -17.4% | 2015-09-11, From 2012-07-01 |
| 2012-06-30 | $24.10M | -28.1% | 2014-09-30, From 2011-07-01 |
| 2011-06-30 | $33.50M | n/a | 2013-09-27, From 2010-07-01 |
| No annual figure between 2009-12-26 and 2011-06-30. | |||
| 2009-12-26 | $16.49M | n/a | 2012-03-14, From 2008-12-28 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $300.27M | +8.7% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $93.77M | -8.9% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $243.77M | -42.5% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $80.28M | -11.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
Compare VXRT, IOVA, VCEL, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗